Updated:
Cardiac Insight
Cardiac Insight — Bellevue-based developer of Cardea SOLO and Cardea 20/20 ECG systems, founded by Dr. Dave Hadley and Dr.
Cardiac Insight
Cardiac Insight was founded in 2013 by Dr. Dave Hadley and Dr. Vic Froelicher. Hadley earned a Ph.D. at Caltech and co-founded Sierra Geophysics before shifting focus to cardiac diagnostics. Froelicher, a cardiologist, helped shape the Stanford Criteria for ECG interpretation. Wealth origin is not publicly disclosed as the firm is a privately held medical device company (firm website). The company develops and markets two core products: Cardea SOLO, a 7-day wearable ambulatory ECG sensor with software-assisted analysis, cleared by the FDA in 2017; and Cardea 20/20, a handheld 12-lead ECG system designed to screen young athletes for cardiovascular issues. The Cardea 20/20 uses the International Consensus Criteria and claims an industry-low false-positive rate of ~2% (per the firm, 2023). Cardiac Insight competes with larger players including iRhythm and Philips in the ambulatory cardiac monitoring market. The firm is based in Bellevue, Washington, and its website references clinical studies and product comparisons with competitors such as the Zio patch and ePatch. Cardiac Insight does not publicly disclose total deployment, AUM, or headcount. In 2021, it joined forces with DreamTech, a global electronic components leader, to support growth (per the firm, 2023). No philanthropic foundations or adjacent operating companies are publicly listed. The structural differentiator is the firm's direct-to-provider distribution model for ECG diagnostic hardware with in-office software analytics, minimizing reliance on third-party diagnostic service providers. This contrasts with competitors like iRhythm, which require sending patient data to a central diagnostic service, while Cardiac Insight lets physicians own data and generate reports in under five minutes during a patient visit.
General information
Firm type
other
Year founded
2013
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Bellevue
Corporate office
Bellevue, WA, United States
Principals
Dr. Dave Hadley
Co-Founder
Dr. Vic Froelicher
Co-Founder
Sector focus
Frequently asked questions
Who are the founders and how do they divide responsibilities at Cardiac Insight?
Cardiac Insight was co-founded by Dr. Dave Hadley and Dr. Vic Froelicher. Hadley, a Caltech Ph.D., previously co-founded Sierra Geophysics and focuses on algorithm development and product innovation. Froelicher is a cardiologist who contributed to the Stanford Criteria for ECG interpretation, shaping the clinical framework behind the Cardea 20/20 system (per the firm, 2023).
What are the primary FDA-cleared products and what conditions do they diagnose?
Cardiac Insight's two FDA-cleared products are the Cardea SOLO (cleared 2017) and Cardea 20/20. Cardea SOLO is a 7-day wearable ambulatory ECG sensor with software-assisted analysis for detecting arrhythmias. Cardea 20/20 is a handheld 12-lead ECG system designed to identify hidden cardiac conditions in athletes, using the International Consensus Criteria and achieving a low false-positive rate of ~2% (per the firm, 2023).
How does Cardiac Insight's distribution model differ from competitors like iRhythm?
Cardiac Insight sells directly to healthcare providers, who can perform analysis in-office using the company's software. The physician retains ownership of patient data. Competitors such as iRhythm typically require sending recorded ECG data to a diagnostic service provider (DSP) for interpretation, which can increase turnaround time and data handling complexity (per the firm, 2023).
What investment stage does Cardiac Insight represent for an early-stage investor?
Cardiac Insight is a privately held medical device company with an approved, commercialized product generating revenue. It is beyond the seed or Series A stage, with a strategic partnership with DreamTech established in 2021. The firm's capital requirements are likely focused on scaling manufacturing, regulatory expansion, and commercial growth rather than R&D-stage risk.
Is Cardiac Insight a family office or an operating company?
Cardiac Insight is an operating medical device company, not a family office. It develops, manufactures, and sells ECG diagnostic products. No information indicates it invests in third-party funds or manages outside capital.
Which markets does Cardiac Insight serve geographically?
Cardiac Insight is headquartered in Bellevue, Washington, United States. The firm's website and clinical references are in English; it does not publicly disclose international regulatory clearances beyond the US FDA. Competitor comparisons mention multiple US-based device manufacturers, suggesting a primary focus on the North American market.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: